Investors sold shares of InVitae Corp (NYSE:NVTA) on strength during trading hours on Friday. $18.23 million flowed into the stock on the tick-up and $61.44 million flowed out of the stock on the tick-down, for a money net flow of $43.21 million out of the stock. Of all equities tracked, InVitae had the 0th highest net out-flow for the day. InVitae traded up $1.96 for the day and closed at $15.58

NVTA has been the topic of several research analyst reports. Zacks Investment Research lowered shares of InVitae from a “buy” rating to a “hold” rating in a research note on Saturday, August 11th. ValuEngine raised shares of InVitae from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 29th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $11.00.

The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.75 and a current ratio of 3.75.

InVitae (NYSE:NVTA) last released its quarterly earnings data on Tuesday, August 7th. The medical research company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.07. InVitae had a negative net margin of 125.03% and a negative return on equity of 111.27%. The firm had revenue of $37.31 million for the quarter, compared to the consensus estimate of $30.70 million. equities analysts anticipate that InVitae Corp will post -2.02 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC raised its holdings in InVitae by 27.2% during the second quarter. ARK Investment Management LLC now owns 8,814,227 shares of the medical research company’s stock worth $64,785,000 after buying an additional 1,886,952 shares during the last quarter. BlackRock Inc. raised its holdings in InVitae by 76.7% during the second quarter. BlackRock Inc. now owns 4,816,353 shares of the medical research company’s stock worth $35,400,000 after buying an additional 2,090,818 shares during the last quarter. Rock Springs Capital Management LP raised its holdings in InVitae by 7.2% during the first quarter. Rock Springs Capital Management LP now owns 1,400,000 shares of the medical research company’s stock worth $6,566,000 after buying an additional 94,000 shares during the last quarter. Millennium Management LLC raised its holdings in InVitae by 694.6% during the second quarter. Millennium Management LLC now owns 536,056 shares of the medical research company’s stock worth $3,940,000 after buying an additional 468,596 shares during the last quarter. Finally, Daiwa SB Investments Ltd. raised its holdings in InVitae by 33.3% during the second quarter. Daiwa SB Investments Ltd. now owns 501,847 shares of the medical research company’s stock worth $3,689,000 after buying an additional 125,322 shares during the last quarter. Hedge funds and other institutional investors own 73.65% of the company’s stock.

InVitae Company Profile (NYSE:NVTA)

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.

Recommended Story: How is a Moving Average Calculated?

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.